In the News

Share
Print

Connect with us

COVID-19: Information for Patients and Caregivers

We're here for you, and continue to provide cancer care to new and current patients. Learn about our response to COVID-19.

What you need to know

1774 News Items found
MSK immunologist Ming Li
Sloan Kettering Institute Scientists Solve a 100-Year-Old Mystery about Cancer

Scientists have long known that cancer cells and immune cells have an uncommon hunger for glucose but haven’t understood why. A new study offers an answer.
Lorenz Studer and Viviane Tabar
Upcoming Clinical Trial Will Test New Cell Therapy for Parkinson’s Disease in Humans

Study will be the first clinical trial testing an investigational stem cell therapy aimed at restoring lost brain cells called neurons in people with advanced Parkinson’s disease (PD).
Finding
Vijai Joseph and Sabine Topka in the lab
Repairing DNA Damage in Cancer Cells

New findings could lead to a different kind of cancer drug that targets a DNA damage repair pathway called nucleotide excision repair.
Francisco Sánchez-Rivera
Confronting a Crisis: How MSK Cancer Geneticists Responded to COVID-19

During World War II, US factories famously converted their operations to support the war effort. COVID-19 instigated something similar among cancer scientists.
Martin S. Tallman, MD
Memorial Sloan Kettering’s Martin S. Tallman, MD, Named American Society of Hematology President

Dr. Tallman will serve a year-long term as President for the American Society of Hematology.
Medical oncologist Nai-Kong Cheung.
Novel Treatment Pioneered by MSK Kids Researchers Receives FDA Approval for Patients with High-Risk Neuroblastoma

The US Food and Drug Administration (FDA) has approved the drug naxitamab (Danyelza) for the treatment of patients with high-risk neuroblastoma. The drug, also known as humanized 3F8, was developed by researchers at MSK Kids, the pediatric cancer program at Memorial Sloan Kettering.
Physician-scientist Nai-Kong Cheung
Caging the Beast: MSK Researchers Design a New Radiation Treatment More Destructive to Cancer Cells

Learn about the work of Nai-Kong Cheung and other MSK scientists who have learned more about how to deliver stronger treatment with less toxicity.
Human metastatic melanoma cells in a lymph node. ENPP1, a protein involved in immune evasion, is shown in green.
Taking the STING Out of Cancer: Discovery about How Cancer Cells Evade Immune Defenses Inspires New Treatment Approach

The research identifies a protein called ENPP1 as a potential drug target in the treatment of advanced cancers with chromosome instability.
Luis A. Diaz, MD, head of the division of Solid Tumor Oncology at MSK
Changing the Standard of Care at MSK and Beyond: New Treatment Option for Advanced Colorectal Cancer

A landmark study led in part by physician-researchers from Memorial Sloan Kettering is giving new hope to some people with metastatic colorectal cancer.
Q&A
Lymphoma expert Gilles Salles
Taking on New Challenges: 8 Questions with Gilles Salles

New Lymphoma Service Chief Gilles Salles discusses his plans for research and collaborations at MSK.